Provided by Tiger Trade Technology Pte. Ltd.

Moleculin Biotech

0.5004
-0.0260-4.94%
Post-market: 0.51260.0122+2.44%19:30 EDT
Volume:720.15K
Turnover:366.41K
Market Cap:9.75M
PE:-0.05
High:0.5498
Open:0.5409
Low:0.4920
Close:0.5264
52wk High:15.75
52wk Low:0.1614
Shares:19.48M
Float Shares:17.03M
Volume Ratio:0.50
T/O Rate:4.23%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-9.5973
EPS(LYR):-28.4188
ROE:-1371.64%
ROA:-84.57%
PB:0.84
PE(LYR):-0.02

Loading ...

Traws Pharma Q2 Revenue Falls to Zero on Licensing Termination; Net Loss Widens

Reuters
·
Aug 15

Moleculin Biotech Q2 EPS $(1.40) Misses $(1.01) Estimate

Benzinga Earnings
·
Aug 14

Moleculin Biotech Expects Cash Position to Fund Operations into Q1 2027

Reuters
·
Aug 14

Moleculin Biotech Reports Interim Miracle Trial Data Showing Higher Remission Rates in Relapsed/refractory AML

Reuters
·
Aug 14

Moleculin Biotech Q2 EPS USD -1.4

THOMSON REUTERS
·
Aug 14

Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal Miracle Trial

THOMSON REUTERS
·
Aug 14

Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial

GlobeNewswire
·
Aug 14

Moleculin Biotech Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 14

Moleculin Net Loss Narrows to $7.64 Million in Q2 FY26; R&D Expense Rises to $5.45 Million

Reuters
·
Aug 14

Moleculin Biotech Inc Expected to Post a Loss of $1.54 a Share - Earnings Preview

Reuters
·
Aug 08

Moleculin Biotech Chief Science Officer Donald H. Picker Acquires Common Shares Worth $129,999.75

Reuters
·
Aug 06

Analysts Offer Insights on Healthcare Companies: Moleculin Biotech (MBRX), Merit Medical Systems (MMSI) and Moderna (MRNA)

TIPRANKS
·
Aug 01

NASDAQ Trade Halt Volatility Trading Pause at 10:12 Am

Reuters
·
Jul 31

Moleculin Biotech Prices Offering with Warrants for 37,130,001 Shares at $0.75 Exercise Price

Reuters
·
Jul 31

Moleculin Biotech - Prices $9.30 Mln Public Offering of Shares and Warrants at $0.75 Per Share

THOMSON REUTERS
·
Jul 31

Moleculin Announces Pricing of $9.3 Million Public Offering

THOMSON REUTERS
·
Jul 31

Moleculin Biotech - no Evidence of Cardiotoxicity Observed with Annamycin in Miracle Trial

THOMSON REUTERS
·
Jul 31

Moleculin Biotech - Miracle Trial Part a Final Treatment Expected September 2026; Unblinded Results December 2026–February 2027

THOMSON REUTERS
·
Jul 31

Moleculin Biotech - Miracle Trial Reports 37% Blinded Crc in Venetoclax-Failed R/R Aml Patients - SEC Filing

THOMSON REUTERS
·
Jul 31

Moleculin Says Miracle Trial Posts 37% Interim CRc Rate in Venetoclax-failed AML Patients

Reuters
·
Jul 31